OPKO Health, Inc. (NASDAQ:OPK) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET

Company Participants

Yvonne Briggs - LHA Investor Relations

Phillip Frost - Chairman and Chief Executive Officer

Elias Zerhouni - President and Vice Chairman

Adam Logal - Senior Vice President and Chief Financial Officer

Charles Bishop - Chief Executive Officer, OPKO Renal

Conference Call Participants

Jeffrey Cohen - Ladenburg Thalmann & Company

Maury Raycroft - Jefferies

Edward Tenthoff - Piper Sandler

Yale Jen - Laidlaw and Company

Dipesh Patel - H.C. Wainwright and Company

Operator

Hello and welcome to the OPKO Health Third Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.

I would like now to turn the conference over to Yvonne Briggs. Please go ahead.

Yvonne Briggs

Thank you, operator. Good afternoon. This is Yvonne Briggs with LHA. Thank you all for joining today's call to discuss OPKO Health's Financial Results for the Third Quarter of 2023. I'd like to remind you that any statements made during this call by management other than statements of historical fact, will be considered forward-looking and as such will be subject to risks and uncertainties that can materially affect the company's expected results.

Those forward-looking statements include without limitation, the various risks described in the company's SEC filings, including the annual report on Form 10-K for the year ended December 31, 2022, and its subsequently filed SEC reports. This conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, November 6th, 2023. Except as required by law OPKO undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call.

Before we begin, let me review the format for today's call, Dr. Phillip Frost, Chairman and Chief Executive Officer will open the call. Dr. Elias Zerhouni, Vice Chairman and President of OPKO will then provide an overview of OPKO's pharmaceutical business as well as BioReference Health, after that, Adam Logal, OPKO's CFO will review the company's third quarter financial results, and then we'll open up the call to questions.

Now I'd like to turn the call over to Dr. Frost.

Phillip Frost

Good afternoon and thank you for joining us today. The third quarter was quite active at OPKO with several key accomplishments. In September, we announced that ModeX was awarded a contract from the Biomedical Advanced Research and Development Authority known as BARDA to develop novel multi-specific antibodies against viral infectious diseases that are deemed to be public health threats.